InOut™ Overview
Why this Capsule
InOut is a novel non-invasive ingestible capsule used to sample localized gastrointestinal microbiota and content for medical diagnostics, treatment, research, and precision medicine for humans and animals.
How it is used
The InOut delayed action and enteric action ingestible capsules are designed to be used in an ambulatory setting. The capsule is recovered from the stool, placed in the protective container, and gets it to an attending lab, clinic, doctor, or researcher for analysis.
The Difference
Endoscopic sampling methods require anesthesia, risk, recovery, and high costs in a clinic or hospital setting. Even then, the most remote areas of the small intestine cannot be reached.
Fecal samples from stool are a complicated amalgamation of the total digestive processes and thwarts advances toward understanding the microbiome and its role in life, health, and disease.
InOut non-invasive methods captures localized upstream microbiota and content from the chyme instead of feces and can be repeated at will with one or more capsules at a time.
InOut Capsules can be used to determine microbiota communities and bodily fluid content before and after diets, during and after medical treatments, and its simplicity makes it a boon to the DNA and microflora testing industry.
InOut is an unparalleled tool for medical diagnostics, treatment, research and individualized medicine. Consider immediate and differing delayed action capsules used alone or in series with one individual or any number of individuals repeatable at home, clinic, or business. Obtain otherwise unavailable samples of microbe stains within their environment; sample virus mRNA before it degrades in the upper intestines. Metagenomics and transcriptomics can finally be used on localized intestinal material.
Animal use update:
InOut for animal use will be available in the 1st quarter, 2022.
InOut™ Capsule
The Idea
The idea for InOut was fostered by my need to sample microbes and bodily fluid located in the small intestine and finding there was no practical way to do it. Present practice and methods are invasive and incomplete. No method exists for non-invasive localized gastrointestinal sampling. Incredibly the medical, clinical, and research professions are limited to samples provided by mouth swabs, anal swabs or stool, and endoscopic procedures.
Worldwide Need
The need is verified by market reports, research and medical publications, and National Science Foundation I-Corp market participation including over 100 interviews with global pharma medical conference attendees, physicians, gastroenterologists, researchers, testing laboratories, and animal health companies.
“All disease begins in the gut.”
―Hippocrates 460 BC ~ 370 BC
A novel, disruptive, medical device.
Additional Information
Assembling the puzzle to achieve commercial production of the InOut capsule has been completed; Animal use deliveries will begin in the 1st quarter, 2022.
We wish to enter into strategic relationships with our technology. We have a robust IP position with a US patent and foreign patents pending.
If you are interested, we can provide a product overview and offer to enter into a NDA with you company to provide you with full details. Our objective is to secure an exclusive period of evaluation and dealing, something we are currently prepared to provide.
